Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Impedimed Limited ( (AU:IPD) ) has shared an announcement.
Impedimed Limited announced a change in the director’s interest, with Fiona Bones acquiring 98,347 ordinary shares, increasing her total holdings to 1,872,746 shares. This acquisition was part of an issue of shares in lieu of 15% of director fees for the quarter ended 30 September 2025, indicating a strategic move to align director interests with company performance.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices. The company’s primary products are designed to measure and monitor fluid status and body composition, with a significant market focus on healthcare providers and patients managing conditions such as lymphedema and heart failure.
Average Trading Volume: 1,808,782
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
See more data about IPD stock on TipRanks’ Stock Analysis page.